Introduction
============

Amyotrophic lateral sclerosis (ALS) is a fast progressing neurodegenerative disorder associated with atrophy of upper and/or lower motor neurons leading to muscle wasting due to denervation. It is the third most frequently occurring neurodegenerative disease after Alzheimer's disease and Parkinson's disease ([@B23]). Death usually occurs within 2--3 years after diagnosis as a result of respiratory failure ([@B12]). Frontotemporal dementia (FTD) on the other hand is characterized by degeneration of neurons in the frontal and temporal lobes and is associated with impairment of cognitive abilities and language, as well as behavioral changes ([@B3]). Today, both diseases fall under the umbrella term of TDP-43 proteinopathies, in reference to the occurrence of cytoplasmic inclusions of the TAR DNA-binding protein 43 (TDP-43) in glial and neuronal cells: 97% of ALS as well as almost 50% of FTD cases present with such TDP-43-positive inclusions ([@B9]; [@B40]). In this pathological state, TDP-43 is found ubiquitinated, truncated, highly phosphorylated and aggregated ([@B1]; [@B49]).

TAR DNA-binding protein 43 is a ubiquitously expressed RNA- and DNA-binding protein. In the central nervous system, TDP-43 binds over 6000 RNA targets. It has been shown to regulate the levels of 600 mRNA species and the alternative splicing of over 950 species ([@B54]). RNA binding is mediated by two RNA recognition motifs, RRM1 and RRM2. In addition, the protein harbors a nuclear export signal (NES) as well as a bipartite NLS, and a C-terminal prion-like glycine-rich domain (**Figures [1A,C](#F1){ref-type="fig"}**) ([@B8]; [@B64]). Mutations in the TDP-43 gene *TARDBP* in ALS were first described in 2008 ([@B19]; [@B29]; [@B56]; [@B61]). The frequency of TDP-43 mutations is 1--5% in both sporadic and familial forms of ALS ([@B20]; [@B29]; [@B31]; [@B25]; [@B71]).

![**Composite nuclear magnetic resonance (NMR) structure of TAR DNA-binding protein 43 (TDP-43). (A)** Human TDP-43 sequence illustrating the nuclear localization sequence (NLS), nuclear export signal (NES), RNA recognition motifs (RRM1 and RRM2), glycine-rich domain, as well as the A90V and M337V mutation sites, and the S409/S410 phosphorylation sites. **(B)** Available NMR solution structures for domains of TDP-43: PDB codes 2N4P, 2CQG, 1WF0, 2N2C ([@B22]; [@B57]; [@B36]; [@B44]; [@B37]; [@B45]). Note that these structures -- as well as the available X-ray structures 4IUF, 4Y00, and 4Y0F ([@B32]; [@B10]) -- do not span the entire sequence, and large portions are either missing or poorly resolved, for example S90 in the largely unstructured terminus of 2CQG at the A90V site. **(C)** Composite TDP-43 schematic of available NMR structures. While iterative homology modeling and loop building techniques were used, a suitable template structure spanning across multiple domains was not found, and this composite structure should be considered as a schematic rather than a confident prediction of folding. Note that in this orientation the S409/S410 phosphorylation site is at the back of the structure near the N-terminus.](fnmol-10-00046-g001){#F1}

The vast majority of *TARDBP* mutations are missense mutations, with all but three located in the C-terminal glycine-rich domain ([@B7]). Two mutations, P112H and D169G, are located in the RRM1 domain ([@B29]; [@B7]; [@B46]). The third, an alanine to valine substitution at residue 90 (A90V), is found between the bipartite NLS ([@B65]; [@B11]). [@B65] showed that the A90V mutation leads to aberrant cytoplasmic localization and decreased solubility of TDP-43, two pathological hallmarks of TDP-43 proteinopathies, *in vitro*. Another study found that under stress conditions, induced pluripotent stem cells with the A90V mutation obtained from an FTD/ALS patient showed increased cell death, cytoplasmic localization of TDP-43 and downregulation of microRNA-9 ([@B69]). However, the variant has been described both in FTD and ALS patients and control individuals ([@B20]; [@B29]; [@B56]; [@B65]; [@B11]). Further studies described the occurrence of the A90V variant at a higher frequency in Alzheimer's disease patients compared to controls ([@B6]; [@B62]). Thus the detection of the A90V variant in healthy controls combined with the biochemical findings reported by [@B65] leave its pathogenic nature unclear.

In this study, we compared the effects of the A90V variant of TDP-43 to both wild-type (WT) and the M337V mutation, a pathogenic mutation associated with familial ALS ([@B56]), in the SH-SY5Y neuroblastoma cell line. We provide evidence that while the A90V amino acid change phenocopies the M337V mutation in terms of cytoplasmic mislocalization, it does not demonstrate such a severe phenotype in terms of formation of insoluble high molecular weight aggregates and C-terminal fragments, pathological phosphorylation or downregulation of TDP-43 targets G3BP and histone deacetylase 6 (HDAC6). We thus conclude that relocalization of TDP-43 from the nucleus to the cytoplasm alone, while a classic pathological feature of TDP-43 proteinopathies, is not in itself sufficient to cause the complete cellular disease signature. Furthermore, we propose that the A90V variant of TDP-43 could be a rare risk factor for ALS that requires another "hit" for the development of the full-blown disease pathology.

Materials and Methods {#s1}
=====================

Plasmids
--------

All plasmids were purchased from and customized by Origene. cDNA sequences were based on the accession number [NM_007375.3](NM_007375.3) for human *TARDBP*. The WT construct was cloned into the pCMV6-AN-myc vector for expression of N-terminally tagged WT or mutant TDP-43 protein. Custom mutagenesis to generate the A90V (point mutation c.269C\>T) and M337V (point mutation c.1009A\>G) TDP-43 amino acid substitutions were carried out by Origene. The presence of each mutation was confirmed by DNA sequencing performed by GENEWIZ (forward sequencing primer 5′-GGACTTTCCAAAATGTCG-3′; reverse sequencing primer 5′-ATTAGGACAAGGCTGGTGGG-3′).

Cell Culture
------------

SH-SY5Y cells were grown at 37°C with 5% CO~2~ in a humidified atmosphere in minimum essential medium (MEM; Thermo Fisher Scientific) supplemented with [L]{.smallcaps}-glutamine, 10% fetal bovine serum and 1% penicillin/streptomycin. Cells were subcultured every 3--4 days. For immunofluorescence analysis, cells were grown on glass coverslips coated with 1 mg/mL poly-*L*-lysine (Sigma) in 24-well plates (Cellstar). For Western blot analysis, cells were grown in 6-well plates (Costar). Cells were transiently transfected using Fugene HD (Promega) following the manufacturer's instructions 24 h after seeding (Fugene HD:DNA ratio 3:1). Total transfection time was 48 h.

Antibodies
----------

The following antibodies were used for immunofluorescence staining: rabbit N-terminal TDP-43 (1:500; 10782-2-AP, Proteintech), mouse anti-myc 9E10 (1:200; Developmental Studies Hybridoma Bank, 1:200: sc-40, Santa Cruz), mouse anti-scaffold attachment factor B (SAFB) 6F7 (1:300; ab8060, Abcam), mouse anti-protein-associated splicing factor (PSF) (1:50; P2860, Sigma), mouse anti-ubiquitin P4D1 (1:50; sc-8017, Santa Cruz). Anti-mouse and anti-rabbit secondary antibodies coupled to Alexa-488, Alexa-555, and Alexa-568 were used for detection (1:300; Thermo Fisher Scientific). For Western blot analysis, the following antibodies were used: rabbit C- and N-terminal TDP-43 (1:2,500; 12892-1-AP, 1:5,000; 10782-2-AP, Proteintech), mouse S409/410 phospho-TDP-43 (1:2,000; CAC-TIP-PTD-M01, Cosmo), mouse α-tubulin (1:15,000; ab80779, Abcam), rabbit HDAC6 (1:1,000; 12834-1-AP, Proteintech), mouse G3BP (1:1,000; 611126, BD Biosciences), mouse acetylated α-tubulin (1:3,000; 12152, Cell Signaling Technologies), mouse GAPDH 6C5 (1:2,000: sc-32233, Santa Cruz). Anti-mouse and anti-rabbit horseradish peroxidase-coupled secondary antibodies were purchased from Jackson Immunoresearch (1:7,000).

Immunofluorescence Staining
---------------------------

Cells were washed in phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde (in PBS) for 15 min followed by permeabilization in 0.25% Triton-X (in PBS) for 10 min. Ten percent normal goat serum (in PBS; Abcam) was used as a blocking reagent. Cells were blocked for 1 h at room temperature and incubated overnight at 4°C in primary antibody solution. The next day, cells were washed with PBS and incubated for 1 h in secondary antibody solution. Coverslips were mounted with Prolong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific). Image acquisition was performed using a Nikon A1 confocal/Eclipse Ti inverted microscope system and NIS Elements software (Nikon).

Sequential Extraction of Insoluble Protein Aggregates
-----------------------------------------------------

The extraction protocol was adapted from [@B14]. Cells were grown in 6-well plates and transfected 24 h after seeding. After 48 h, transfected cells were lysed in 300 μL radio-immunoprecipitation assay (RIPA) buffer supplemented with 2 mM EDTA, 1 mM EGTA, protease inhibitors (Complete, Roche), and phosphatase inhibitors (PhosStop, Roche). Lysates were sonicated 2x 15 s with 20% maximum amplitude and centrifuged for 30 min at 100,000 × *g* and 4°C (Beckman Optima TLX ultracentrifuge with TLA100.3 rotor and Delrin adaptors). The supernatant was collected as the RIPA-soluble fraction. The pellet was washed in RIPA buffer and centrifuged for an additional 30 min at 100,000 × *g* and 4°C. The supernatant was discarded and the pellet was re-extracted in 100 μL urea buffer \[7 M urea, 2 M thiourea, 30 mM Tris pH 8.5, 4% 3-\[(3-Cholamidopropyl) dimethylammonio\]-1-propanesulfonate (CHAPS, Sigma)\]. The samples were sonicated 2x 15 s and centrifuged at room temperature for 30 min at 100,000 × *g*. The supernatant was collected as the urea-soluble fraction.

Immunoblotting
--------------

Cells were lysed in RIPA buffer supplemented with 2 mM EDTA, 1 mM EGTA, protease inhibitors (Complete, Roche) and phosphatase inhibitors (PhosStop, Roche), and the protein concentration was determined by bicinchoninic acid (BCA) assay. RIPA and urea fractions obtained from sequential extractions were diluted 1:1 with RIPA buffer. Proteins were separated using standard Tris-glycine SDS-PAGE gels (polyacrylamide concentrations 8% for HDAC6, all others 10%) and transferred onto nitrocellulose (BioRad) or polyvinylidene difluoride (PVDF; Millipore) membranes. All blocking and antibody incubation steps were performed either in 5% milk in Tris-buffered saline (TBS) supplemented with 0.1% Tween-20 (TBS-T) or in 3% bovine serum albumin (BSA) in TBS-T. Western blots were developed with enhanced chemiluminescent substrates (ECL). Digital images were acquired with a ChemiDoc MP imaging system (BioRad) and quantified with Image Lab 5 (BioRad). Where necessary, blots were stripped with stripping buffer for 15 min (Restore, Thermo Fisher Scientific) and reprobed with loading control antibodies.

Composite NMR Structure
-----------------------

The composite schematic of the full structure of human TDP-43 was produced from the nuclear magnetic resonance (NMR) structures 2N4P ([@B44], [@B45]), 2CQG ([@B57]), 1WF0 ([@B22]), and 2N2C ([@B36]; [@B37]) \[obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB; [@B4])\] via iterative homology modeling and loop building using the Molecular Operating Environment (MOE) software ([@B42]).

Statistical Analysis
--------------------

All data were expressed as mean ± standard error of the mean (SEM). Statistical analyses were performed using GraphPad Prism 6 software (San Diego, CA, USA). Normality was established using the Shapiro--Wilk test. Mean differences between groups were analyzed by one-way ANOVA and Tukey's multiple comparisons test. The threshold for statistical significance was *p* ≤ 0.05. Experiments were replicated a minimum of three times.

Results
=======

*In silico* Analysis of TDP-43 Protein and Determining Whether It Can Predict the Impact of Mutations on Protein Structure
--------------------------------------------------------------------------------------------------------------------------

Nuclear magnetic resonance and X-ray structural analysis of individual domains of WT and mutant TDP-43 continue to reveal insights into the relationships between disease-related mutations and the biophysical stability of the protein. We reasoned that assembling a three-dimensional model of TDP-43 may help us predict the structural impact of the A90V variant and support our *in vitro* efforts in elucidating its effects. Thus, we attempted to collate all structural information obtained from NMR and X-ray crystallography available in the public domain and obtain a complete 3D model of TDP-43 (**Figure [1](#F1){ref-type="fig"}**). However, structures including all domains which might enable a comprehensive examination of the effects of specific mutations on overall structure and stability are challenging and not yet realized. The human TDP-43 sequence (**Figure [1A](#F1){ref-type="fig"}**) and NMR structures (**Figure [1B](#F1){ref-type="fig"}**) in **Figure [1](#F1){ref-type="fig"}** highlight the NLS, NES, RRM1, RRM2, glycine-rich domain, as well as the A90V and M337V mutation sites and the S409/S410 phosphorylation site ([@B22]; [@B57]; [@B32]; [@B36]; [@B44], [@B45]; [@B10]; [@B37]). The piecewise solutions of NMR and X-ray structures provide valuable domain-level information, but key portions of the protein remain either unresolved or missing. Iterative homology modeling and loop building techniques can be used to infer composite structures from their individual domains. However, in the case of TDP-43 a suitable template structure spanning across multiple domains does not exist, prohibiting the ability to confidently assess the overall structure (only an approximate schematic of the overall structure is shown, **Figure [1C](#F1){ref-type="fig"}**) and thus the impact of the A90V and M337V amino acid substitutions. Without *a priori* assumptions of the impact of the A90V variant based on a complete model, we then proceeded to investigate the consequences of expressing the A90V variant on common pathological phenotypes associated with disease: cytoplasmic relocalization, and the formation of insoluble TDP-43 and TDP-43 protein fragments. We contrasted the A90V variant with the well-characterized mutant M337V, which causes autosomal-dominant familial ALS ([@B56]).

The TDP-43 A90V Variant Phenocopies the M337V Variant by Causing Cytoplasmic Relocalization of TDP-43
-----------------------------------------------------------------------------------------------------

According to [@B65], transient expression of the A90V variant of TDP-43 in QBI-293 cells results in the aberrant relocalization from the nucleus to the cytoplasm. We first verified expression of N-terminally myc-tagged TDP-43 constructs in SH-SY5Y cells by Western blot using an N-terminal TDP-43 antibody (**Figure [2A](#F2){ref-type="fig"}**). Steady state levels of total TDP-43 protein were significantly increased in cells expressing M337V mutant TDP-43 compared to WT expressing cells (0.46 ± 0.19-fold increase over WT; Tukey's multiple comparisons analysis; *p* = 0.04), whereas there was no significant difference in cells expressing the A90V TDP-43 variant compared to WT protein (0.17 ± 0.09-fold over WT; Tukey's multiple comparisons analysis; *p* = 0.57; **Figure [2B](#F2){ref-type="fig"}**; one-way ANOVA, *F*~2,15~ = 3.757; *P* = 0.0316). We confirmed that this increase in M337V TDP-43 protein levels was not caused by increased levels of mRNA, which were comparable between genotypes (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![**The A90V and M337V variants of TDP-43 promote equivalent levels of cytoplasmic relocalization. (A)** Western blot of total overexpressed N-terminally myc-tagged TDP-43 WT, A90V and M337V (oe) and endogenous TDP-43 (endo). **(B)** Quantification of total TDP-43 levels (*N* = 6). **(C)** Immunofluorescence staining of SH-SY5Y cells transiently transfected with WT-, A90V- or M337V-TDP-43. Cells were co-stained with anti-myc (green) and anti-TDP-43 (red) antibodies. Nuclei were visualized with DAPI (blue). Scale bar = 30 μm. **(D)** Quantification of proportion of transfected cells with cytoplasmic TDP-43 localization. Results represent mean number of cells with cytoplasmic TDP-43 ± SEM (*N* = 3). **(E)** Immunofluorescence staining of TDP-43-positive nuclear puncta. Cells with multiple small inclusions or few larger inclusions are indicated with asterisk and arrowhead, respectively. **(F)** Quantification of transfected cells with punctate nuclear TDP-43 inclusions. Results represent mean number of transfected cells with inclusions ± SEM (*N* = 4).^∗^*p* \< 0.05 (One-way ANOVA followed by Tukey's multiple comparisons test).](fnmol-10-00046-g002){#F2}

We then performed immunofluorescence staining of transiently transfected cells in order to confirm the relocalization phenotype observed by [@B65] (**Figures [2C,D](#F2){ref-type="fig"}**). In agreement with the previous report ([@B65]), we observed a significant increase in the proportion of cells with cytoplasmic TDP-43 localization in A90V, compared to WT TDP-43 expressing cells (WT: 28.4 ± 3.0% of cells; A90V: 41.7 ± 3.7% of cells; Tukey's multiple comparisons analysis; *p* = 0.041). Interestingly, the proportion of transfected cells with cytoplasmic TDP-43 localization with A90V was very similar compared to the highly pathogenic mutant M337V (WT: 28.4 ± 3.0% of cells; M337V: 43.0 ± 1.6% of cells; Tukey's multiple comparisons analysis; *p* = 0.028; one-way ANOVA *F*~2,6~ = 7.679; *P* = 0.0222; **Figure [2D](#F2){ref-type="fig"}**).

The M337V Mutant, but Not the A90V Mutant, Enhances the Formation of Nuclear TDP-43 Inclusions
----------------------------------------------------------------------------------------------

In a small number of transfected cells analyzed by immuno fluorescence staining we detected a punctate staining pattern for TDP-43 in the nucleus (**Figure [2E](#F2){ref-type="fig"}**). These TDP-43-positive puncta were only rarely observed in SH-SY5Y cells transfected with WT TDP-43 (0.28 ± 0.10% of transfected cells), but were found in significantly higher numbers in cells expressing the pathogenic mutant M337V (2.00 ± 0.60% of transfected cells; Tukey's multiple comparisons analysis; *p* = 0.049; **Figure [2F](#F2){ref-type="fig"}**). However, we saw no significant difference in puncta formation between WT and A90V TDP-43 expressing cells (A90V: 1.06 ± 0.44% of transfected cells; Tukey's multiple comparisons analysis; *p* = 0.44; one-way ANOVA *F*~2,9~ = 3.94; *P* = 0.059). In order to more closely investigate the composition of these TDP-43-containing puncta, we performed co-staining experiments with two nuclear markers: the nuclear stress body marker SAFB and the paraspeckle marker PSF (**Figure [3](#F3){ref-type="fig"}**). We qualitatively distinguished between transfected cells with small, numerous nuclear TDP-43-positive puncta (**Figure [2E](#F2){ref-type="fig"}**, asterisk; **Figures [3A--C](#F3){ref-type="fig"}**, lower panel) and cells with few, but large, puncta (**Figure [2E](#F2){ref-type="fig"}**, arrowhead; **Figures [3A--C](#F3){ref-type="fig"}**, upper panel). We observed no co-localization between TDP-43 protein and either SAFB or PSF in small puncta (**Figures [3A,B](#F3){ref-type="fig"}**). In cells harboring large TDP-43-positive puncta, both SAFB and PSF were found to be excluded from these structures. We hypothesized that these puncta represent intranuclear inclusions of insoluble, aggregated TDP-43 protein. As aggregated TDP-43 is found pathologically ubiquitinated ([@B49]), we stained myc-TDP-43-transfected cells with an anti-ubiquitin antibody (**Figure [3C](#F3){ref-type="fig"}**). As expected, we detected diffuse ubiquitin staining in both the nucleus and cytoplasm. Both small and large TDP-43 nuclear puncta were shown to co-localize with ubiquitin, indicating that they are *bona fide* aggregates of ubiquitinated TDP-43 protein.

![**TAR DNA-binding protein 43-positive nuclear puncta are inclusions of aggregated TDP-43, and do not co-localize with paraspeckles or nuclear stress bodies.** Co-localization of TDP-43-positive puncta with **(A)** paraspeckle marker polypyrimidine tract-binding protein-associated splicing factor (PSF), **(B)** nuclear stress body marker scaffold attachment factor B (SAFB), **(C)** ubiquitin. Left panels show representative images of cells with numerous small nuclear puncta, right panels cells with few, large puncta. All images shown represent M337V-transfected cells. Wild-type (WT) and A90V-transfected cells with puncta showed identical co-localization or lack thereof. Scale bar = 10 μm.](fnmol-10-00046-g003){#F3}

The A90V TDP-43 Variant Has Subtle Effects on Protein Solubility and Pathologic Phosphorylation Compared to the M337V Mutation
------------------------------------------------------------------------------------------------------------------------------

In order to further investigate how the A90V and M337V mutations affect the cell biology of TDP-43, we measured a range of cellular phenotypes which have been implicated in disease pathogenesis. Initially, we looked at the formation of insoluble TDP-43 aggregates. We fractionated lysates of transfected SH-SY5Y cells into RIPA-soluble and RIPA-insoluble, urea-soluble fractions by high speed centrifugation and separated proteins by SDS-PAGE. We used a TDP-43 antibody recognizing the N-terminus of TDP-43 to assess total TDP-43 protein levels in the RIPA and urea fractions (**Figure [4A](#F4){ref-type="fig"}**). In line with previous reports ([@B28]; [@B5]; [@B26]), we found that the M337V mutation caused accumulation of insoluble TDP-43 in the urea fraction compared to WT (3.21 ± 1.14-fold increase over WT; Tukey's multiple comparisons analysis; *p* = 0.023; one-way ANOVA *F*~2,9~ = 5.38; *P* = 0.029). While an enrichment of TDP-43 in the urea fraction was also observed in A90V-expressing cells (1.59 ± 0.38-fold increase compared to WT), the increase was not statistically significant (Tukey's multiple comparisons analysis; *p* = 0.283; **Figure [4B](#F4){ref-type="fig"}**).

![**The A90V TDP-43 variant has subtle effects on protein solubility and phosphorylation compared to the M337V variant. (A)** Western blot of total TDP-43 (N-terminal antibody) and phospho-S409/S410 TDP-43 in radio-immunoprecipitation assay (RIPA)-soluble (R) and RIPA-insoluble, urea-soluble (U) fractions. **(B,C)**, Western blot quantification of **(B)** total TDP-43 and **(C)** phospho-TDP-43 normalized to total TDP-43 in insoluble fractions. All results represent mean band signal ± SEM. ^∗^*p* \< 0.05 (*N* = 4, One-way ANOVA followed by Tukey's multiple comparisons test).](fnmol-10-00046-g004){#F4}

We used a phospho-specific TDP-43 antibody raised against the disease-relevant phosphorylation sites at S409/S410 ([@B48]) to assess the phosphorylation status of the insoluble TDP-43 protein species (**Figure [4A](#F4){ref-type="fig"}**). We normalized the phospho-signal in the urea-soluble fractions to the total TDP-43 detected in these fractions to control for the relative increase in insoluble TDP-43 protein in mutant expressing cells (**Figure [4C](#F4){ref-type="fig"}**). Immunoblotting with this antibody revealed significantly increased phosphorylation levels at the S409/S410 residues in the urea-soluble fraction of M337V TDP-43 expressing cells compared to cells expressing WT TDP-43 (6.38 ± 2.56-fold increase compared to WT; Tukey's multiple comparisons analysis; *p* = 0.036). We detected a non-statistically significant increase in S409/S410 phosphorylation in cells transfected with the A90V variant (1.35 ± 0.48-fold increase compared to WT; Tukey's multiple comparisons analysis; *p* = 0.80; one-way ANOVA *F*~2,9~ = 5.015; *P* = 0.0344). Taken together, these results indicate that while the A90V and M337V mutations induce similar levels of cytoplasmic relocalization of TDP-43, a pathology commonly associated with disease, the effects of the M337V variant on protein solubility and phosphorylation are far greater than those of the A90V mutation. In fact there looks to be a spectrum of pathology in these transfected cell models with WT and M337V TDP-43 at the opposite extremes, with the A90V TDP-43 somewhere in between, in the absence of any additional stressors.

M337V Mutant TDP-43 Readily Forms C-Terminal Fragments Compared to A90V and WT
------------------------------------------------------------------------------

In addition to abnormal phosphorylation as well as decreased protein solubility and aberrant cellular localization, another pathological feature of TDP-43 is the formation of C-terminal truncated protein fragments ([@B49]; [@B40]; [@B21]). In order to detect C-terminal protein fragments not picked up by the N-terminal TDP-43 antibody used in **Figure [4](#F4){ref-type="fig"}** we extracted soluble and insoluble TDP-43 from transfected SH-SY5Y cells and used a C-terminal antibody (**Figures [5A,B](#F5){ref-type="fig"}**). We identified two smaller protein species present only in TDP-43-transfected cells, but not in the vector control cells (**Figure [5B](#F5){ref-type="fig"}**). The larger fragment ran close to the 34 kDa marker, while the smaller fragment ran close to the 26 kDa marker. C-terminal TDP-43 fragments with molecular weights of 35 kDa (CTF35) and 25 kDa (CTF25) have been described in a variety of cellular and animal models ([@B64]; [@B66]; [@B5]; [@B13]; [@B17]; [@B34]), and we will thus refer to the identified truncated TDP-43 species as CTF35 and CTF25. We quantified the amount of both fragments in the RIPA-soluble and urea-soluble fractions. We normalized to the amount of full-length TDP-43 in each sample in order to account for the increase of total TDP-43 protein. In the RIPA-soluble fraction, we observed an accumulation of CTF35 in M337V-transfected cells compared to either WT or A90V-TDP-43 (2.03 ± 0.44-fold increase over WT, *p* = 0.005; 0.68 ± 0.25-fold increase over A90V, *p* = 0.044; Tukey's multiple comparisons analysis; one-way ANOVA *F*~2,6~ = 13.94; *P* = 0.0056; **Figure [5C](#F5){ref-type="fig"}**). However, we did not detect a significant increase of the smaller CTF25 in mutant-transfected cells (M337V: 1.09 ± 0.6-fold increase over WT, *p* = 0.19; 0.64 ± 0.52-fold increase over A90V, *p* = 0.36; Tukey's multiple comparisons analysis; one-way ANOVA *F*~2,6~ = 2.166; *P* = 0.196). In the urea-soluble fractions the effect of the M337V mutant on the formation of these C-terminal fragments was even more striking: we detected a 20.0 ± 6.6-fold increase in the 25 kDa fragment in the M337V mutant compared to WT (Tukey's multiple comparisons analysis; *p* = 0.026) and a 4.3 ± 1.7-fold increase compared to the A90V variant (Tukey's multiple comparisons analysis; *p* = 0.049; one-way ANOVA *F*~2,6~ = 7.657; *P* = 0.0223; **Figure [5D](#F5){ref-type="fig"}**). We could not detect any 35 kDa fragment in the urea fraction of WT-TDP-43 transfected cells and found a 5.4 ± 1.1-fold increase in CTF35 levels in M337V- compared to A90V-transfected cells (M337V compared to WT: *p* = 0.0008: compared to A90V: *p* = 0.0019; Tukey's multiple comparisons analysis; one-way ANOVA *F*~2,6~ = 31.53; *P* = 0.0007).

![**The M337V TDP-43 variant readily forms C-terminal fragments compared to A90V and WT. (A,B)** Western blot of TDP-43 with C-terminal antibody for detection of C-terminal fragment. **(A)** short exposure, **(B)** longer exposure revealing 35 kDa fragment (CTF35) and 25 kDa fragment (CTF25). **(C,D)** Western blot quantification of TDP-43 fragment CTF35 **(C)** and CTF25 **(D)** (red boxes indicate quantified bands). All results represent mean band signal ± SEM. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 (*N* = 3, One-way ANOVA followed by Tukey's multiple comparisons test).](fnmol-10-00046-g005){#F5}

The M337V TDP-43 Variant Down-regulates the Expression of G3BP and HDAC6
------------------------------------------------------------------------

We hypothesized that the M337V mutant of TDP-43 not only impacts TDP-43 localization and post-translational modifications in a manner more detrimental than the A90V variant, but that the downstream functional consequences of expressing M337V TDP-43 might reflect this more severe phenotype. Such a functional consequence could be altered regulation of transcriptional targets of TDP-43. Previous studies have shown that both depletion of endogenous TDP-43 as well as overexpression of R361S mutant TDP-43 lead to a decrease in G3BP, a regulator of stress granule assembly ([@B41]; [@B2]). We investigated expression levels of G3BP following 48 h of TDP-43 overexpression and found that only M337V, but not A90V, mutant TDP-43 significantly downregulated G3BP compared to WT TDP-43 and mock control (25.8 ± 8.3% compared to WT, *p* = 0.01; 23.0 ± 7.8% compared to mock, *p* = 0.03; Tukey's multiple comparisons analysis; one-way ANOVA *F*~3,20~ = 4.861; *P* = 0.0106; **Figures [6A,C](#F6){ref-type="fig"}**). Furthermore, levels of HDAC6, a known target of TDP-43 that is likewise downregulated upon TDP-43 silencing ([@B18]), were significantly reduced in M337V TDP-43 expressing cells compared to cells transfected with WT and A90V TDP-43 or mock-transfected controls (WT: 36.1 ± 13.6%; *p* = 0.017; A90V: 35.6 ± 12.3%; *p* = 0.02; mock: 43.0 ± 10.2%; *p* = 0.002; Tukey's multiple comparisons analysis; one-way ANOVA *F*~3,12~ = 8.455; *P* = 0.0027; **Figures [6B,D](#F6){ref-type="fig"}**). We also probed for levels of acetylated α-tubulin, a substrate for HDAC6 ([@B24]), but found no significant increase in acetylated α-tubulin levels in M337V-transfected cells compared to WT (*p* = 0.99) or A90V (*p* = 0.99) TDP-43 (Tukey's multiple comparisons analysis; **Figures [6B,E](#F6){ref-type="fig"}**), suggesting that the decrease in HDAC6 protein levels in M337V-expressing cells is not sufficient to impair acetylation of α-tubulin. In comparison to mock-transfected controls, both WT and A90V-transfected cells showed a small, but significant upregulation of acetylated α-tubulin (WT: 15.8 ± 4.5%, *p* = 0.05; A90V: 16.0 ± 3.8%, *p* = 0.04; Tukey's multiple comparisons analysis) and M337V-transfected cells showed a similar trend (14.2 ± 5.2%, *p* = 0.08; one-way ANOVA *F*~3,20~ = 3.833; *P* = 0.0256). An increase in α-tubulin acetylation has been described in conditions of cellular stress ([@B39]), which could be caused by the overexpression of TDP-43 irrespective of mutation. In conclusion, the M337V variant of TDP-43, but not the A90V variant, impacted the expression of known targets of TDP-43 in a manner consistent with the effects of a knockdown of TDP-43 function.

![**The M337V, but not the A90V variant, leads to a downregulation of G3BP and HDAC6.** Western blots of **(A)** G3BP, **(B)** HDAC6 and acetylated α-tubulin levels in SH-SY5Y cells expressing WT, A90V and M337V TDP-43 or cells transfected with myc control vector. **(C--E)** Densitometry analyses of **(C)** G3BP (*N* = 6), **(D)** HDAC6 (*N* = 4), and **(E)** acetylated α-tubulin levels (*N* = 6). All results represent mean band signal ± SEM. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 (One-way ANOVA followed by Tukey's multiple comparisons test).](fnmol-10-00046-g006){#F6}

Discussion
==========

To date, genetic studies have revealed 52 missense mutations in the TDP-43 gene *TARDBP* as well as one insertion/deletion and one nonsense mutation ([@B7]). While most mutations cluster in the C-terminal glycine-rich domain, the A90V amino acid exchange lies in the bipartite NLS. The pathogenic nature of this variant remains uncertain; *in vitro* studies suggest that A90V-TDP-43 is more prone to cytoplasmic mislocalization and aggregation, two pathological changes associated with ALS and FTD ([@B65]). Furthermore, expression of A90V TDP-43 fails to fully ameliorate the pupal lethality and neuronal loss phenotypes caused by loss of the Drosophila ortholog of *TARDBP* ([@B62]). Genetic studies, however, have revealed the presence of the A90V variant both in patients suffering from ALS and FTD as well as in healthy controls ([@B20]; [@B29]; [@B56]; [@B65]; [@B11]). It is thus likely that A90V is not a highly penetrant disease-associated mutation, but a genetic risk factor for TDP-43 proteinopathies. In order to gain a deeper understanding of the pathogenic potential of the A90V variant, we initially conducted analyses of available structural information for TDP-43 to see if we could generate hypotheses to test based on the site of the mutations. But unfortunately, due to the lack of complete NMR and X-ray structures, we were unable to predict the impact of the A90V variant of TDP-43 *in silico* (**Figure [1](#F1){ref-type="fig"}**). We then resorted to more traditional *in vitro* studies to measure TDP-43 mislocalization, changes in protein solubility and phosphorylation, and the effects on their expression on known targets of TDP-43. We compared the impact of A90V with that of the M337V mutation, a disease-associated mutation frequently used for *in vitro* and *in vivo* studies of ALS pathogenesis ([@B35]; [@B70]; [@B5]; [@B26]; [@B47]).

When we initially looked to reproduce the nuclear localization phenotype observed by [@B65] we found an almost identical increase in the number of cells with cytoplasmic TDP-43 with both the A90V and M337V variants. Thus, we concluded that the A90V variant of TDP-43 phenocopies the cytoplasmic relocalization phenotype associated with ALS found in the disease-associated M337V mutant. This strong effect is perhaps not surprising given the fact that the A90V variant lies within the bipartite NLS and could thus potentially interfere with nucleo-cytoplasmic shuttling of TDP-43.

In a small subset of transfected cells, we detected dot-like structures in the nucleus that stained positive for TDP-43. These TDP-43-positive nuclear structures were observed more frequently in cells transfected with the M337V, but not the A90V, mutant compared to WT. Instances of defined, patterned nuclear staining of TDP-43 *in vitro* have been described in the literature: overexpression of certain deletion mutants or the M337V mutant has been shown to cause the formation of nuclear inclusions of aggregated TDP-43 ([@B64]; [@B51]; [@B59]), while other papers describe co-localization of TDP-43 with nuclear bodies under certain circumstances, such as stress bodies under heat shock conditions, or NEAT1_2-containing paraspeckles ([@B50]; [@B60]). We sought to define the nature of the observed nuclear TDP-43-positive puncta by performing co-localization experiments using antibodies against SAFB as a marker of nuclear stress bodies and PSF as a paraspeckle marker. We did not observe co-localization of either SAFB or PSF with TDP-43-positive inclusions, indicating that WT and mutant TDP-43 are not recruited into nuclear stress bodies or paraspeckles. However, we found that nuclear puncta of TDP-43 co-stain with ubiquitin, suggesting that they represent inclusions of aggregated, ubiquitinated TDP-43 in the nucleus. In this light, the increased frequency of these TDP-43-positive inclusions in the M337V mutant is probably the result of a higher aggregation propensity.

We investigated the aggregation propensity of the A90V and M337V mutants further by sequential extraction of total cell lysates. We found a stark increase in M337V in the insoluble fraction, in line with published literature showing increased aggregate formation of M337V-TDP-43 *in vitro*, *in vivo*, and in culture systems ([@B28]; [@B70]; [@B5]). Compared to WT protein, the increase we observed in insoluble A90V TDP-43 was not statistically significant. Phosphorylation levels of insoluble, aggregated TDP-43 species at the pathologically relevant S409/410 residues were also markedly increased in the M337V mutant, while the effect in the A90V mutant was modest and not statistically significant. Analysis of total unfractionated lysate also revealed a significant increase in total mutant M337V TDP-43 protein compared to WT, likely due to the longer half-life of M337V-TDP-43 previously reported ([@B38]; [@B63]). While this increase in total M337V mutant protein could possibly help drive some of the described phenotypes, we believe the modest effect size (less than 50% compared to WT, less than 20% compared to A90V) is not sufficient to cause some of the more striking phenotypes we have observed, such as the effects on G3BP and HDAC6 expression levels.

C-terminally cleaved TDP-43 fragments are another pathological hallmark of ALS and FTD, and expression of TDP-43 in cell culture models can give rise to cleavage products of 35 and 25 kDa in the absence or presence of various stressors ([@B49]; [@B21]; [@B11]; [@B67]; [@B34]). We found an enrichment of two fragments of approximately 35 and 25 kDa in the insoluble fraction of M337V-transfected cells compared to both WT and A90V. Almost no C-terminal fragments were detected in the insoluble fraction of A90V-transfected cells, suggesting that A90V-TDP-43 is less prone to protease cleavage compared to the familial ALS mutant M337V. This phenotype is especially striking as several papers have suggested a crucial role for C-terminal TDP-43 fragments in enhancing cellular toxicity and aggregation propensity, especially the 25 kDa fragment ([@B27]; [@B52]; [@B68]; [@B30]).

In addition to the effects of the A90V variant on TDP-43 aggregation, post-translational modifications and truncation, we investigated changes in known targets of TDP-43. We found that protein levels of G3BP are reduced in SH-SY5Y cells expressing M337V, but not A90V TDP-43. G3BP is a component of cytoplasmic stress granules, transient structures made from proteins and untranslated mRNAs, which form after insults such as heat shock and oxidative stress ([@B53]; [@B58]). Similarly, we found that only the M337V, but not the A90V mutant, leads to a reduction of the histone deacetylase HDAC6 in SH-SY5Y cells; HDAC6 has previously been claimed to be a critical component of stress granule assembly ([@B33]). TDP-43 has been shown to be both recruited to and to regulate assembly of stress granules ([@B15]; [@B41]). That the A90V variant of TDP-43, in contrast to the M337V variant, does not cause a downregulation of G3BP or HDAC6 could suggest that A90V does not interfere with stress granule assembly and dynamics, while the disease-associated M337V mutant does. In this regard, the M337V mutant causes a loss of normal function of TDP-43 regulation of stress granule assembly -- while the A90V variant does not. Structurally, stress granules are protein-rich liquid droplets formed in a process termed liquid-liquid phase separation (LLPS). Recent studies have shown that mutations in the C-terminal domain, including the M337V mutation, inhibit this droplet formation by interrupting the interaction of α-helixes, driving the proteins to form aggregates instead ([@B43]; [@B16]; [@B55]). Since the A90V variant is far removed from the α-helix in the C-terminal domain, it is likely that it does not interfere with the helical contact that drives droplet formation. However, further studies will be required to investigate whether A90V has more subtle effects on TDP-43 LLPS, droplet formation, and stress granule assembly.

In summary, the results of this study show that the A90V variant of TDP-43, which has been described as a rare variant found both in ALS and FTD patients and healthy controls, shows modest effects on protein solubility, phosphorylation, and truncation when compared to the disease-causing M337V mutation. In addition, in contrast to the M337V mutant, the A90V variant does not cause impairment of HDAC6 or G3BP expression. These findings are especially striking since we observed comparable levels of cytoplasmic TDP-43 relocalization in both A90V- and M337V-transfected cells, suggesting that cytoplasmic relocalization of TDP-43 protein is not by itself sufficient to cause the other molecular phenotypes associated with disease. Furthermore, we speculate that due to these modest *in vitro* effects observed with the A90V variant, carriers might not develop a disease phenotype in the absence of a "second hit." However, it is possible that the A90V mutant could lower the threshold required for an additional stressor or other genetic risk factor to cause the catastrophic effects on TDP-43 and its functions observed in ALS and FTD. Thus, we conclude that the A90V variant of TDP-43 could be a rare genetic risk factor for TDP-43 proteinopathies. However, further studies will be required to gain an insight into the interplay between A90V as a genetic risk factor and other genetic and environmental risk factors associated with ALS and FTD.
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